LONZA GROUP UNSP.ADR 1/10 - Asset Resilience Ratio
LONZA GROUP UNSP.ADR 1/10 (LO3A) has an Asset Resilience Ratio of 3.04% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See LONZA GROUP UNSP.ADR 1/10 current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2022–2024)
This chart shows how LONZA GROUP UNSP.ADR 1/10's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see LONZA GROUP UNSP.ADR 1/10 balance sheet assets.
Liquid Assets Composition Over Time
This chart breaks down LONZA GROUP UNSP.ADR 1/10's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read LO3A total liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €600.00 Million | 3.04% |
| Total Liquid Assets | €600.00 Million | 3.04% |
Asset Resilience Insights
- Limited Liquidity: LONZA GROUP UNSP.ADR 1/10 maintains only 3.04% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
LONZA GROUP UNSP.ADR 1/10 Industry Peers by Asset Resilience Ratio
Compare LONZA GROUP UNSP.ADR 1/10's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
GeneDx Holdings Corp.
NASDAQ:WGS |
Diagnostics & Research | 15.00% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Healius Ltd
AU:HLS |
Diagnostics & Research | 0.06% |
|
Microba Life Sciences Ltd
AU:MAP |
Diagnostics & Research | 11.53% |
|
Genetic Signatures Ltd
AU:GSS |
Diagnostics & Research | 60.91% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
Annual Asset Resilience Ratio for LONZA GROUP UNSP.ADR 1/10 (2022–2024)
The table below shows the annual Asset Resilience Ratio data for LONZA GROUP UNSP.ADR 1/10.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 3.04% | €600.00 Million ≈ $701.46 Million |
€19.73 Billion ≈ $23.07 Billion |
+1.85pp |
| 2023-12-31 | 1.19% | €200.00 Million ≈ $233.82 Million |
€16.85 Billion ≈ $19.70 Billion |
-3.91pp |
| 2022-12-31 | 5.10% | €885.00 Million ≈ $1.03 Billion |
€17.36 Billion ≈ $20.29 Billion |
-- |
About LONZA GROUP UNSP.ADR 1/10
Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics; Small Molecules; Cell & Gene; and Capsules & Health Ingredients segments. The Biologics segment engages in the contract develo… Read more